Ibrutinib Capsules

VELCADE monotherapy is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

Monotherapy is indicated for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

VELCADE monotherapy is indicated in patients with Waldenstrm's macroglobulinemia who have received at least one prior therapy.

Or first-line treatment for patients with Waldenstrom's macroglobulinemia who are not candidates for chemoimmunotherapy.

VELCADE, in combination with rituximab, is indicated for the treatment of patients with Waldenstrom's macroglobulinemia.